Medicxi announces 500 million-euro Fund V
UK-based life sciences venture capital firm Medicxi today announced the closing of Medicxi V, a 500 million-euros ($579.5 million) fund dedicated to building and backing innovative European biotechnology companies with clear product visions to transform patient care.
The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi’s pioneering asset-centric investment model.
Medicxi has created 16 new companies, delivered over 20 positive clinical data readouts and has realiizd over $1 billion across its portfolio since its last fundraise, including from investments in Vaxcyte, Merus and Abivax, and the acquisitions of ViceBio (Sanofi [Euronext: SAN]), Versanis Bio (Eli Lilly (NYSE: LLY]) and ProfoundBio (Genmab [Nasdaq: GMAB]).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze